ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...8384858687888990919293...129130»
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical, Journal, Combination therapy, Monotherapy:  Pharmacometric analysis of tribendimidine mono- and combination therapies to achieve high cure rates in patients with hookworm infections. (Pubmed Central) -  Jun 22, 2021   
    For the monotherapy and combination with oxantel pamoate arm, E models adequately described the correlation between dADT exposure and probability to be cured, with a required exposure to achieve 50% of maximum effect of 39.6 and 15.6 nmol/mL*h, respectively.Based on our simulations an unrealistically high monotherapy tribendimidine dose would be necessary to achieve CRs >90%, while combination therapy with ivermectin would meet this desired target product profile. Further clinical studies should be launched to develop this combination for the treatment of hookworm and other helminth infections.
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical, Review, Journal:  Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. (Pubmed Central) -  Jun 22, 2021   
    Certain studies have highlighted the significance of ivermectin in COVID-19; however, it requires evidences from more Randomised Controlled Trials (RCTs) and dose- response studies to support its use. In silico-based analysis of ivermectin's molecular interaction specificity using AI and classical mechanics simulation-based methods indicates positive interaction of ivermectin with viral protein targets, which is leading for SARS-CoV 2 N-protein NTD (nucleocapsid protein N-terminal domain).
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical, PK/PD data, Preclinical, Journal:  Safety and pharmacokinetic assessments of a novel ivermectin nasal spray formulation in a pig model. (Pubmed Central) -  Jun 22, 2021   
    The fast attainment of high and persistent IVM concentrations in nasopharyngeal tissue is the main advantage of the nasal over the oral route. These original results support the undertaking of future clinical trials to evaluate the safety/efficacy of the nasal IVM spray application in the prevention and/or treatment of COVID-19.
  • ||||||||||  Journal:  Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective. (Pubmed Central) -  Jun 22, 2021   
    Thus, in this current computational study we carried out molecular docking experiments to assess the bridging potentials of some commercial drugs such as chloroquine, hydroxychloroquine, lopinavir, ritonavir, nafamostat, camostat, famotidine, umifenovir, nitazoxanide, ivermectin, and fluvoxamine at the interface between human ACE2 and the coronavirus spike glycoprotein complex...Ivermectin, nafamostat, and camostat with binding energy values -9.0 kcal/mol, -7.8 kcal/mol, and -7.4 kcal/mol respectively were the hit drugs on the coronavirus spike glycoprotein. Nafamostat showed a dual bridging potential against ACE2 and spike glycoprotein, and could therefore be a promising lead compound in the prevention and control of this disease.
  • ||||||||||  hydroxychloroquine / Generic mfg., ivermectin oral / Generic mfg.
    Journal:  Molecular docking and dynamics studies of curcumin with COVID-19 proteins. (Pubmed Central) -  Jun 22, 2021   
    chloroquine, hydroxychloroquine, ivermectin, artemisinin, remdesivir, azithromycin considered for clinical trials, there has been an inherent need to find distinctive antiviral mechanisms of these drugs...Furthermore, representative docking complexes were validated using molecular dynamics simulations and mechanistic studies at 100 ns was carried on nucleocapsid and nsp10 proteins with curcumin complexes which resulted in stable and efficient binding energies and correlated with that of docked binding energies of the complexes. Both the docking and simulation studies indicate that curcumin has the potential as an antiviral against COVID-19.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  COVID-19 and Ivermectin: Potential threats associated with human use. (Pubmed Central) -  Jun 22, 2021   
    The potential toxicity and careful dosage analyses are urgently required before declaring it as an anti-SARS-CoV-2 drug candidate. This paper overviews the background and potential threats associated with the off-label use of IVM as prophylactic drug or treatment option against COVID-19.
  • ||||||||||  ivermectin oral / Generic mfg.
    Enrollment open:  I-TECH: Ivermectin Treatment Efficacy in Covid-19 High Risk Patients (clinicaltrials.gov) -  Jun 21, 2021   
    P4,  N=500, Recruiting, 
    This paper overviews the background and potential threats associated with the off-label use of IVM as prophylactic drug or treatment option against COVID-19. Not yet recruiting --> Recruiting